FDA Clearance Expands Access to Non-Invasive Pain Management

Magstim has received FDA clearance for its non‑invasive magnetic stimulation device, offering a regulated, drug‑free option for chronic pain management in the United States.

Clinically, the clearance validates a non‑implant neuromodulation modality deployable without systemic medications, offering an alternative to opioids and other pharmacotherapies.

This addresses a clear treatment gap for adults with persistent pain who remain symptomatic despite conservative care. Unlike implanted neuromodulation or systemic therapies, the device delivers targeted external stimulation—making it most relevant for patients with chronic, intractable, post‑surgical, or post‑traumatic pain who have exhausted standard physical therapy, medications, and interventional procedures.

The device delivers focused magnetic stimulation to peripheral nerves and adjacent neural circuits to modulate nociceptive signaling. Applied magnetic pulses induce brief electric fields in targeted nerve fibers, intended to reduce abnormal excitability and alter synaptic transmission implicated in chronic pain. The expected physiologic effect is attenuation of pain signal amplification with downstream improvements in function and quality of life.